The α7 subtype of the nicotinic acetylcholine receptor (nAChR) is considered important in higher cognitive functions, and cholinergic loss underpins the pathophysiology of Alzheimer’s disease (AD). However, the relationships between α7 nAChR function and clinical functions or amyloid-β (Aβ) deposition remain to be explored in the living AD brain.
Objective:
We aimed to elucidate the relationship between α7 nAChR availability in the specific cholinergic region and cognitive decline in the Aβ-confirmed AD brain.
Methods:
Twenty AD patients and ten age-matched healthy subjects were examined. The α7-nAChR availability and Aβ deposition were evaluated using positron emission tomography with an α7 nAChR radiotracer 11C-(R)-MeQAA and 11C-Pittsburg compound B (11C-PiB), respectively. Semi-quantified values of tracer binding were estimated with a simplified reference tissue method for BPND of 11C-(R)-MeQAA and a tissue ratio method for SUVR of 11C-PiB. These parameters and clinical scores were compared voxel-wise using a statistical parametric mapping method.
Results:
The levels of 11C-(R)-MeQAA BPND in the temporal and prefrontal cholinergic projection regions were significantly lower in AD, and negative correlations were found between 11C-PiB SUVR and 11C-(R)-MeQAA BPND in the region of the nucleus basalis magnocellularis and medial prefrontal cortex. Levels of 11C-(R)-MeQAA BPND were significantly correlated with memory and frontal function scores in AD.
Conclusion:
The association between Aβ burden and α7-nAChR reduction in the basal forebrain cholinergic system was highlighted in relation to cognitive decline in AD. This suggests that Aβ-linked α7-nAChR reduction is clinico-pathophyisologically important for considering a good therapeutic target in AD.
PicciottoMR, CaldaroneBJ, KingSL, ZachariouV (2000) Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology22, 451–465.
4.
LougheadJ, RayR, WileytoEP, RuparelK, SanbornP, SiegelS, GurRC, LermanC (2010) Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry67, 715–721.
5.
DunbarGC, InglisF, KuchibhatlaR, SharmaT, TomlinsonM, WamsleyJ (2007) Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) . J Psychopharmacol21, 171–178.
OkadaH, OuchiY, OgawaM, FutatsubashiM, SaitoY, YoshikawaE, TeradaT, OboshiY, TsukadaH, UekiT, WatanabeM, YamashitaT, MagataY (2013) Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer’s aetiopathology. Brain136, 3004–3017.
8.
Hellström-LindahlE, MousaviM, ZhangX, RavidR, NordbergA (1999) Regional distribution of nicotinic receptor subunit mRNAs in human brain: Comparison between Alzheimer and normal brain. Brain Res Mol Brain Res66, 94–103.
9.
MarutleA, GillbergPG, BergforsA, YuW, NiR, NennesmoI, VoytenkoL, NordbergA (2013) 3H-deprenyl and3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid inAlzheimer brain. J Neuroinflammation10, 861.
10.
YuWF, GuanZZ, BogdanovicN, NordbergA (2005) High selective expression of α7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer’s disease and patients carrying Swedish APP 670/671 mutation: A possible association with neuritic plaques. Exp Neurol192, 215–225.
11.
GottiC, MorettiM, BohrI, ZiabrevaI, VailatiS, LonghiR, RigantiL, GaimarriA, McKeithIG, PerryRH, AarslandD, LarsenJP, SherE, BeattieR, ClementiF, CourtJA (2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis23, 481–489.
Martin-RuizCM, CourtJA, MolnarE, LeeM, GottiC, MamalakiA, TsouloufisT, TzartosS, BallardC, PerryRH, PerryEK (1999) α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer’s disease. J Neurochem73, 1635–1640.
14.
GuanZZ, ZhangX, RavidR, NordbergA (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem74, 237–243.
15.
BurghausL, SchützU, KrempelU, de VosRA, Jansen SteurEN, WeversA, LindstromJ, SchröderH (2000) Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res76, 385–388.
16.
WeversA, BurghausL, MoserN, WitterB, SteinleinOK, SchützU, AchnitzB, KrempelU, NowackiS, PilzK, StoodtJ, LindstromJ, De VosRA, Jansen SteurEN, SchröderH (2000) Expression of nicotinic acetylcholine receptors in Alzheimer’s disease: Postmortem investigations and experimental approaches. Behav Brain Res113, 207–215.
17.
TeaktongT, GrahamA, CourtJ, PerryR, JarosE, JohnsonM, HallR, PerryE (2003) Alzheimer’s disease is associated with a selective increase in α7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia41, 207–211.
18.
TeaktongT, GrahamAJ, CourtJA, PerryRH, JarosE, JohnsonM, HallR, PerryEK (2004) Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer’s disease and dementia with Lewy bodies: Differential neuronal and astroglial pathology. J Neurol Sci225, 39–49.
19.
OgawaM, NishiyamaS, TsukadaH, HatanoK, FuchigamiT, YamaguchiH, MatsushimaY, ItoK, MagataY (2010) Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor α7 subtype. Nucl Med Biol37, 347–355.
20.
HortiAG, GaoY, KuwabaraH, WangY, AbazyanS, YasudaRP, TranT, XiaoY, SahibzadaN, HoltDP, KellarKJ, PletnikovMV, PomperMG, WongDF, DannalsRF (2014) 18F-ASEM a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET. J Nucl Med55, 672–677.
21.
IsobeT, YamadaR, ShimizuK, SaitoA, OteK, SakaiK, MoriyaT, YamauchiH, OmuraT, WatanabeM (2012) Development of a New brain PET scanner based on single event data acquisition. Proceedings of Nuclear Science Symposium. Medical Imaging Conference & Workshop on Room-Temperature Semiconductor X-Ray and Gamma-Ray Detectors, Anaheim, California, 3540–3.
22.
YoshikawaE, AndoI, KosugiT, KakimotoA, IsobeT, OteK, OkadaH, OuchiY (2015) α7 nicotinic receptor imaging using a new fixation-free PET system. Proceedings of 101st Scientific assembly and Annual Meeting; November 29-December 4; Chicago, USA, p. 325.
23.
OmuraT, MoriyaT, YamadaR, YamauchiH, SaitoA, SakaiT, MiwaT, WatanabeM (2012) Development of a high-resolution four-layer DOI detector using MPPCs for brain PET. IEEE NSS-MIC Conf Rec, pp. 3560–3563.
24.
BreeseCR, AdamsC, LogelJ, DrebingC, RollinsY, BarnhartM, SullivanB, DemastersBK, FreedmanR, LeonardS (1997) Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol387, 385–398.
MaiJK, AssheuerJ, PaxinosG (1997) Atlas of the Human Brain. Academic Press, San Diego.
27.
ZaborszkyL, HoemkeL, MohlbergH, SchleicherA, AmuntsK, ZillesK (2008) Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage42, 1127–1141.
28.
OuchiY, KannoT, OkadaH, YoshikawaE, FutatsubashiM, NobezawaS, TorizukaT, SakamotoM (1999) Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson’s disease: A double-tracer positron emission tomography study. Ann Neurol46, 723–731.
YokokuraM, MoriN, YagiS, YoshikawaE, KikuchiM, YoshiharaY, WakudaT, SugiharaG, TakebayashiK, SudaS, IwataY, UekiT, TsuchiyaKJ, SuzukiK, NakamuraK, OuchiY (2011) In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging38, 343–351.
31.
KikuchiM, HirosawaT, YokokuraM, YagiS, MoriN, YoshikawaE, YoshiharaY, SugiharaG, TakebayashiK, IwataY, SuzukiK, NakamuraK, UekiT, MinabeY, OuchiY (2011) Effects of brain amyloid deposition and reduced glucose metabolism on the default mode of brain function in normal aging. J Neurosci31, 11193–11199.
32.
GallezotJD, BottlaenderM, GregoireMC, RoumenovD, DeverreJR, CoulonC, OttavianiM, DolléF, SyrotaA, ValetteH (2005) In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med46, 240–247.
33.
MeyerPM, StreckerK, KendziorraK, BeckerG, HesseS, WoelplD, HenselA, PattM, SorgerD, WegnerF, LobsienD, BarthelH, BrustP, GertzHJ, SabriO, SchwarzJ (2009) Reduced α4β2-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry66, 866–877.
34.
BucknerRL, SnyderAZ, ShannonBJ, LaRossaG, SachsR, FotenosAF, ShelineYI, KlunkWE, MathisCA, MorrisJC, MintunMA (2005) Molecular, structural, and functionalcharacterization of Alzheimer’s disease: Evidence for arelationship between default activity, amyloid, and memory. J Neurosci25, 7709–7717.
35.
WongDF, KuwabaraH, PomperM, HoltDP, BrasicJR, GeorgeN, FrolovB, WillisW, GaoY, ValentineH, NandiA, GapasinL, DannalsRF, HortiAG (2014) Human brain imaging of α7 nAChR with [18F]ASEM: A new PET radiotracer for neuropsychiatry and determination of drug occupancy. Mol Imaging Biol16, 730–738.
36.
CourtJA, Martin-RuizC, GrahamA, PerryE (2000) Nicotinic receptors in human brain: Toography and pathology. J Chem Neuroanat20, 281–298.
37.
IkonomovicMD, KlunkWE, AbrahamsonEE, WuuJ, MathisCA, ScheffSW, MufsonEJ, DeKoskyST (2011) Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology77, 39–47.
38.
JackCRJr, LoweVJ, WeigandSD, WisteHJ, SenjemML, KnopmanDS, ShiungMM, GunterJL, BoeveBF, KempBJ, WeinerM, PetersenRC, Alzheimer’s Disease Neuroimaging Initiative (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain132, 1355–1365.
39.
VillainN, ChetelatG, GrassiotB, BourgeatP, JonesG, EllisKA, AmesD, MartinsRN, EustacheF, SalvadoO, MastersCL, RoweCC, VillemagneVL (2012) AIBL Research Group. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: A voxelwise PiB-PET longitudinal study. Brain135, 2126–2139.
40.
WangHY, LeeDH, D’AndreaMR, PetersonPA, ShankRP, ReitzAB (2000) β-Amyloid(1-42) binds to α7 nicotinicacetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem275, 5626–5632.
41.
NageleRG, D’AndreaMR, AndersonWJ, WangHY (2002) Intracellular accumulation of β-amyloid(1-42) in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience110, 199–211.
42.
DuboisB, SlachevskyA, LitvanI, PillonB (2000) The FAB: A Frontal Assessment Battery at bedside. Neurology55, 1621–1626.
43.
LiebermanJA, DunbarG, SegretiAC, GirgisRR, SeoaneF, BeaverJS, DuanN, HosfordDA (2013) A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology38, 968–975.
44.
BuchananRW, ConleyRR, DickinsonD, BallMP, FeldmanS, GoldJM, McMahonRP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry165, 82–89.
